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Background: Tuberculosis (TB) is a major public health problem that accounts for almost half a million human
immunodeficiency virus (HIV) associated deaths. Provision of isoniazid preventive therapy (IPT) is one of the public
health interventions for the prevention of TB in HIV infected individuals. However, in Ethiopia, the coverage and
implementation of IPT is limited. The objective of this study is to compare the incidence rate of TB, TB-free survival
time and identify factors associated with development TB among HIV-infected individuals on pre-ART follow up.
Methods: A retrospective cohort study was conducted from January, 2008 to February 31, 2012 in Jimma hospital.
Kaplan-Meier survival plots were used to calculate the crude effect in both groups on TB-free survival probabilities
and compared using the log rank test. A Cox proportional hazard model was used to identify predictors of TB.
Result: A total of 588 patients on pre-ART care (294 IPT and 294 non-IPT group) were followed retrospectively for a
median duration of 24.1 months. The median CD4
+ cell count was 422 cells/μl (IQR 344 – 589). During the follow up
period, 49 individuals were diagnosed with tuberculosis, giving an overall incidence of 3.78 cases per 100 person
year (PY). The incidence rate of TB was 5.06 per 100 PY in non-IPT group and 2.22 per 100 PY in IPT user group.
Predictors of higher TB risk were: being on clinical WHO stage III/IV (adjusted hazard ratio (AHR = 3.05, 95% confidence
interval (CI): 1.61, 5.81); non-IPT user (AHR = 2.02, 95% CI: 1.04, 3.92); having CD4
+ cell count less than 350 cells/μl
(AHR = 3.16, 95% CI: 1.04, 3.92) and between 350–499 cells/μl, (AHR = 2.87; 95% CI: 1.37 - 6.03) and having
episode of opportunistic infection (OI) in the past (AHR = 2.41, 95% CI: 1.33-4.34).
Conclusion: IPT use was associated with fifty percent reduction in new cases of tuberculosis and probability
of developing TB was higher in non-IPT group. Implementing the widespread use of IPT has the potential to
reduce TB rates substantially among HIV-infected individuals in addition to other tuberculosis prevention and
control effort in resource limited settings.
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Tuberculosis remains a major public health problem
throughout the world. Globally almost one third of the
world population is estimated to be latently infected
with Mycobacterium tuberculosis and hence at risk of
developing active TB disease [1].
The TB epidemic has been fuelled by HIV co-infection,
one increasing the other’s impact.
HIV infection, through waning of the immune system,
increases the susceptibility mycobacterium tuberculosis
infection and progression to active disease [2]. The TB
epidemic is further, aggravated by drug resistance, social
inequalities, limited TB control efforts and limited access
to health care services [3,4]. The risk of developing TB is
between 20 to 37 times greater in HIV infected individuals
when compared to immunocompetent individuals [5]. As
a result, TB is the commonest infection and common
cause of death among HIV-infected individuals [6].
According to the world health organization (WHO)
2013 global TB report, there were an estimated 8.6 mil-
lion new TB cases and 1.3 million TB related deaths (a
quarter of these deaths were associated with HIV). More
than half of these estimated TB cases occurred in Asia
and western pacific regions. HIV positive TB cases accounts
for 1.1 million (13% of all TB cases) among patients with
documented HIV test result. Majority of the co-infected
cases (75%) were in Africa. Nearly 57% of HIV positive TB
cases were on ART and 520,000 HIV-positive people were
reported to have received TB preventive therapy. South
Africa accounts for the highest proportion of IPT coverage
(71%) [6]. This report also shows that Ethiopia ranks sev-
enth amongst the world’s 22 high TB burden countries in
the world and TB is the second leading cause of hospital
death in the country [6,7]. In Ethiopia, 79% of HIV in-
fected individuals were screened for active TB, of whom
15% had TB/HIV co-infection. Only 19% of the HIV posi-
tive clients without active TB were provided with IPT in
2010 [7,8]. This dual epidemic of HIV/AIDS and TB is a
growing concern that challenges the Ethiopian govern-
ment’s efforts towards prevention and control of both dis-
ease [7,9,10].
To reduce the burden of TB among HIV infected indi-
viduals, the country had adopted twelve key TB/HIV col-
laborative activities recommended by World Health
Organization (WHO) [5-7,11]. Provision of ART signifi-
cantly reduces TB/HIV related mortality and risk of inci-
dent TB [5,12]. However ART alone isn’t adequate enough
in reducing tuberculosis risk in HIV infected individuals,
hence implementation of other TB specific intervention to
further reduce the risk of TB in HIV-infected individuals
is required [5,12-14].
Multiple studies have demonstrated the effectiveness
of IPT in adults [9,11,13,15-18]. Meta-analyses of ran-
domized controlled trials have shown that IPT reducesthe risk of TB by 33% overall and by 64% when targeted
to HIV infected individuals who had a positive tubercu-
lin skin test [13]. An earlier (1998) systematic review of
four placebo controlled randomized trials, concluded
that approximately one half of active tuberculosis cases
were reduced with use of IPT [19]. Cohort and case
control studies have shown that IPT provision for
HIV-infected adults significantly reduce tuberculosis
incidence independently or with coadministration of highly
active antiretroviral therapy (HAART) [11,15-17,20,21].
In contrary three cohort studies conducted in Brazil,
Tanzania, and Kenya showed IPT had no significant
effect on the reduction of TB among HIV-infected in-
dividuals [22-24].
In spite of good evidence of IPT uses and the global
recommendation as part of standard care for all HIV in-
fected individuals after ruling out active TB, it was noted
that the coverage and implementation had been slow in
many countries including Ethiopia [7,9,18]. These prob-
lems were linked with concern about development of
isoniazid related resistance, drug side effects, providers’
attitude on its effectiveness, failure to consistently use
TB screening algorithms and shortage of drug supplies
[18,25,26]. These factors may affect both the perception
and attitude of the policy makers, health care providers
and clients towards TB preventive therapy. Studies that
have shown inconsistent results of IPT protection
against TB may cause further misunderstanding. A crit-
ical review of barriers related to the health system and
client related issues should be carried out in order to de-
velop nation specific strategies that are essential to foster
the implementation of IPT program. In Ethiopia the ef-
fect of IPT on the incidence of TB and the determinants
associated with TB disease among HIV infected individ-
uals (pre-ART) are not well studied. Furthermore little is
known on TB free survival probability among IPT user
and non-users. Therefore this study is aimed at investi-
gating IPT effect and identifying determinants factors for
TB among HIV-infected individual in Jimma University
Specialized Hospital (JUSH), in southwest Ethiopia. The
study was based on the hypothesis that there is no signifi-
cant difference in TB incidence between IPT user and
non-user among HIV-infected individuals.
Methods
Study setting and design
Jimma University Specialized Hospital (JUSH) is a gov-
ernment hospital, rendering its referral and specialized
medical services to more than 15 million populations in
south western Ethiopia. The hospital has enrolled more
than 7,400 patients to HIV care and follow-up, among
these 3,476 were on pre-ART care follow-up during the
study period. A retrospective cohort study design was
employed in this study.
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The source population was HIV infected individuals en-
rolled in pre-ART care follow-up, whose age was between
15 and 64 years. The study population was a sample of the
source population who was under care during the period
January 2008 to February 2012. Exclusion criteria were in-
complete patient records, past history of TB, active TB, or
on treatment for TB.
Sample size determination
The sample size was determined using sample size deter-
mination formula for independent cohort studies using
Epi-info version 7, for IPT and non-IPT group. Incidence
of TB among IPT group 2.2% and among non-IPT group
7.5% were taken from previous study [27]. Taking ratio
of exposed to unexposed 1:1 with 80% power and 5%
type I error, the resulting total sample size was 588.
The total number of adult patients in pre-ART care
was obtained from the pre-ART register (N = 3476) and
patients were categorized according to IPT (n1 = 420)
and non-IPT group (n2 = 2648). Sampling frame for IPT
and non-IPT group was prepared by assigning sequen-
tially unique number to each patient medical record in
each groups separately; simple random sampling method
was employed to select participant records from both
groups using computer generated random numbers.
Variables and source of data
The main outcome variable was tuberculosis. Diagnosis
of TB in HIV positive individuals in this analysis was
based on the national guidelines for clinical and pro-
grammatic management of TB, TB/HIV and leprosy in
Ethiopia. Smear-positive pulmonary TB was established
if at least one sputum smear examination positive for
Acid-fast bacilli (AFB). The algorithm for smear negative
pulmonary TB diagnosis required at least three sputum
specimens negative for AFB, radiologic abnormalities
consistent with active tuberculosis, decision by a clin-
ician to treat with full course of Anti-TB chemotherapy,
or patient with AFB smear-negative sputum which is
culture-positive for MTB. Extra pulmonary TB diagnosis
was based on histological or strong clinical evidence
consistent with active extra pulmonary, with the clini-
cian’s decision to treat the patient with a full course of
anti-tuberculosis treatment or one specimen from an
extra pulmonary site culture or smear positive for AFB.
For this analysis, both pulmonary TB and extra pulmon-
ary TB were included [7].
The primary exposures of interest were initiation of
IPT. Prior to initiating IPT in HIV-infected individuals,
it is important to screen for TB. As a screening tool, the
Ethiopian guidelines suggest a four symptoms based
clinical algorithm that comprises of current cough, night
sweats, weight loss and fever. HIV infected individualswithout any of the symptoms are unlikely to have active
TB and should be offered IPT. IPT is provided for a
period of six months, with monthly follow-up until the
treatment course is completed [7]. However tuberculin
skin test (TST) isn’t a requirement for IPT initiation in
the country [7]. We extracted data on these and other
predictor variables from standard national pre-ART
register, follow up forms and other clinical records.
These register and forms are regularly filled as part of a
routine paper-based patient record system. Important
data related to socio-demographic characteristics (age,
sex, marital status, level of education, religion, residence,
employment status). clinical, laboratory and IPT infor-
mation (past OI, clinical WHO stage, CD4
+ cells count,
weight, other OI treatment initiation, Hgb, IPT and
functional status, incident TB). Social condition and sub-
stance use (number of people in the household, tobacco
use, alcohol use, soft drugs and hard drugs) were ex-
tracted by trained nurses.
Data processing and analysis
Completed questionnaires were coded, entered and ana-
lyzed using STATA version 11.1 software. Each variable
was checked for missing and coding problem. Descrip-
tive statistics was used to summarize the characteristics
of the cohort.
TB incidence rate was calculated for IPT and non-IPT
group in HIV-infected individuals. The TB free survival
probability (survival analysis) was calculated in months
using the time interval between dates registered on pre-
ART care or IPT prophylaxis initiation to date of TB
diagnosis or censoring. Subject was censored on the date
of completion of the study, died, lost to follow-up, trans-
ferred out and ART initiated; whichever occurred first.
For subjects lost to follow-up, transferred out and died,
the date of their last follow-up visit was used as the cen-
soring date.
Kaplan-Meier survival plots were used to calculate the
crude effect of both groups on TB-free survival probabil-
ities and compared using the log rank test. Crude hazard
ratio test was used for inclusion of variables into multivari-
ate analysis with cut off p-value ≤ 0.25. Cox proportional
hazard model was used to identify factors associated with
incidence of TB and a p-value ≤ 0.05 declares the signifi-
cance of the variables at 95% confidence level.
The multivariate model was built using purposeful selec-
tion with backward elimination method [28]. Confounding
was checked and percentage change in the regression
coefficients (β) less than 20% reveals absence of con-
founder [28]. Interaction for the main effect model was
checked and Partial likelihood ratio test has p-value > 0.05
and VIF < 10 indicating non-existence of multicollinearity
among the variables in this study. A statistical and graph-
ical test was used to assess the proportional hazard
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dictors violated the proportional hazard assumptions and
there was no strong evidence of non-fit.
Ethical consideration
The research was approved by Institutional Review Board of
Mekelle University, College of Health Science (MU-CHS)
with reference number ERC 0228/2013. A support letter
referred with BEFO/HBTFH/1-8/2234 was sought from
Oromia Regional Health Bureau. Jimma University
Specialized Hospital was informed about the objective of
the study and written permission was obtained from the
hospital administrator before starting data collection.
All the collected patient information was stored an-
onymous and data was kept confidential. More over per-
sonal identifiers was not included in the data collection
forms.
Results
A total of 588 HIV infected individuals (294 IPT and 294
non- IPT cohort) were followed for a median duration of
22.61 (IQR 17.13-28.56) months in the IPT and 26.68
(IQR 14.66-43.66) months in the non-IPT group (Table 1).
Among the IPT group, majority of the patients 180
(61.43%) were female. Similarly among the non-IPT group,
females accounted for 62.59%. At the time of enroll-
ment to pre-ART care, there were 124 (42.18%) and 133
(45.24%) patients under age of 29 years in the IPT and
non-IPT groups, respectively (Table 1).
Clinical and laboratory characteristics, and follow-up
outcome
Nearly half of the patients had at least one episode of
opportunistic illness in the past, 145 (49.49%) of them
were from IPT and 126 (42.86%) were from non-IPT
group. Out of the total study participants, majority of
IPT group patients were in clinical WHO stage I/II 256
(87.07%). The median CD4+ cell count was 422 cells/μl
(IQR 344 – 589) for the entire cohort, 415 cells/μl (IQR
328–786) for IPT group, 444 cells/μl (IQR 357–613) for
non-IPT group.
Out of 237 (40.51%) patients who had CD4+ cell count
between 350–499 cells/μl, 121 (41.44%) were in IPT
group and 116 (39.59%) of them were in non-IPT group
(Table 2).
Comparison of TB incidence rate and TB-free survival
time
There were 49 incident TB cases in this study cohort
during 1297.5 PY of observation and the overall tubercu-
losis incidence rate was 3.78 per 100 PY of follow up
(95% CI: 2.85, 4.99 cases per 100 PY). The TB incidence
rate in the IPT group was 2.22 new cases of TB per 100
person-year (95% CI: 1.29, 3.82 cases per 100 PY) and5.06 per 100 person-year (95% CI: 3.65, 7.02 cases per
100 PY) for non IPT group (Table 3). Individuals tak-
ing isoniazid preventive therapy were at lower risk of
developing tuberculosis as compared to their counter
parts with adjusted hazard ratio (AHR) of 2.02 (95% CI:
1.04 -3.92) (Table 4).
The TB free survival proportion for the entire cohort
over the follow up period was 0.77 and the TB-free sur-
vival probability in the IPT user group was significantly
higher than the non-IPT user group throughout the study
(log rank statistic = 4.20, df =1, P = 0.0403) (Figure 1). Fur-
thermore Figure 1 shows the cumulative TB-free survival
at thirty six months of follow-up was approximately 93%
in IPT and 87% non-IPT user groups.Predictors of tuberculosis incidence
HIV infected individuals who didn’t received IPT during
the study period had two times higher risk of developing
TB as compared to those who received IPT, after adjusting
for past opportunistic illness, clinical WHO stage and
CD4
+ cell count (AHR = 2.02; 95% CI: 1.04-3.92). The
presence of past episode of opportunistic illness were also
associated with increased hazard of developing TB after
controlling for IPT use, clinical WHO stage and CD4
+ cell
count (AHR = 2.41; 95% CI: 1.33-4.34) (Table 4).
Individuals with clinical WHO stage III/IV had nearly
3.1 times increased risk of developing TB as compared to
patients in clinical WHO stage I/II after controlling for
past opportunistic illness, IPT use and CD4
+ cell count
(AHR = 3.05; 95% CI: 1.61- 5.81). Compared to those pre-
senting with CD4
+ cell count > =500 cells/μl, patients with
CD4
+ cell count less than 350 cells/μl had 3.2 times (AHR=
3.16; 95% CI: 1.04 - 3.92) and between 350 – 499 cells/μl
had 2.9 times (AHR = 2.87; 95% CI: 1.37 - 6.03) higher
hazard of developing TB after controlling for past oppor-
tunistic illness, clinical WHO stage and IPT use (Table 4).
In summary, HIV infected individuals with advanced
clinical WHO stage, non-IPT use, low CD4+ cell count
and history of past episode of opportunistic illness, were
more likely to have higher incidence of TB (Table 4).Discussion
The overall incidence of tuberculosis was 3.78 per
100PY in the entire follow-up period. This finding was
consistent with a cohort study in Zambia that shows 3.6
per 100 PY [29]. However, this result was higher than
study done in Brazil and Ethiopia with TB incidence 2.28
per 100 PY 2.6 per 100 PY, respectively [17,22]. This in-
consistency might be due to smaller number of individ-
uals receive IPT, some of the study participants were
taking ART and difference in source population, as the
source population of those study includes all age groups
in the latter studies [17,22].
Table 1 Demographic, socio-economic, substance use characteristics of the study participants in pre-ART follow up,
JUSH, 2013, N = 588
Variables Category pre-ART Total
IPT group no (%) Non-IPT group no (%)
Age group (years) 15-29 124 (42.18%) 133 (45.24%) 257 (43.71%)
30-39 108 (36.73%) 93 (31.63%) 201 (34.18%)
39+ 62 (21.09%) 68 (23.13%) 130 (22.11%)
Sex (n = 587) Female 180 (61.43%) 184 (62.59%) 364 (62.01%)
Male 113 (38.57%) 110 (37.41%) 223 (37.99%)
Residence (n = 585) Urban 201 (69.07%) 201 (68.37%) 402 (68.72%)
Rural 90 (30.93%) 93 (31.63%) 183 (31.28%)
Marital status Never Married 51 (17.35%) 54 (18.37%) 105 (17.86%)
Married 159 (54.08%) 156 (53.06%) 315 (53.57%)
Separated 31 (10.54%) 21 (7.14%) 52 (8.84%)
Divorced 31 (10.54%) 29 (9.86%) 60 (10.20%)
Widowed 22 (7.48%) 34 (11.56%) 56 (9.52%)
Level of education (n = 585) No education 53 (18.21%) 86 (29.25%) 139 (23.76%)
Primary 123 (42.27%) 111 (37.76%) 234 (40.00%)
Secondary 86 (29.55%) 71 (24.15%) 157 (26.84%)
Tertiary 29 (9.97%) 26 (8.84%) 55 (9.40%)
Religion (n = 587) Protestant 35 (11.95%) 50 (17.01%) 85 (14.48%)
Orthodox 174 (59.39%) 133 (45.24%) 307 (52.30%)
Muslim 78 (26.62%) 104 (35.37%) 182 (31.01%)
Catholic 6 (2.05%) 7 (2.38%) 13 (2.21%)
Employment status (n = 585) Employed 116 (39.86%) 104 (35.37%) 220 (37.61%)
Unemployed 175 (60.14%) 190 (64.63%) 365 (62.39%)
People/household (n = 583) <=2 89 (30.38%) 92 (31.72%) 181 (31.05%)
>2 204 (69.62%) 198 (68.28%) 402 (68.95%)
Substance use
Tobacco Yes 37 (12.63%) 57 (19.39%) 94 (16.01%)
No 256 (87.37%) 237 (80.61%) 493 (83.99%)
Alcohol Yes 64 (21.77%) 74 (25.17%) 138 (23.47%)
No 230 (78.23%) 220 (74.83%) 450 (76.53%)
Soft drugs1 Yes 92 (31.29%) 110 (37.41%) 202 (34.35%)
No 202 (68.71%) 184 (62.59%) 386 (65.65%)
Hard drugs2 Yes 31 (10.58%) 33 (11.26%) 64 (10.92%)
No 262 (89.42%) 260 (88.74%) 522 (89.08%)
Follow up time median (IQR) Over all 24.08 (IQR = 15.63-36.98) month
IPT 22.61 (IQR = 17.13-28.56) month
Non-IPT 26.68 (IQR = 14.66-43.66) month
1khat, “shisha”, pills 2cocaine, morphine, intravenous drug use.
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patients with no prophylaxis as compared to patients
with IPT prophylaxis. This finding was in agreement
with studies done in Namibia, Brazil and Ethiopia
[9,11,16,17,21]. However, a cohort study in Thailand and
clinical trial in Kenya showed, there was no difference inTB incidence whether a patient took IPT or not [24,30].
This difference might be explained by limited scope
focusing only to see incidence of pulmonary type of tu-
berculosis cases in Thailand study [30]. Similarly, the
benefit of isoniazid might be limited in the Kenya study
due to high rate of transmission of new infection and
Table 2 Clinical and laboratory characteristics, and follow-up outcome of the study participants on Pre-ART follow up,
JUSH, 2013, N = 588
Variables Category Pre-ART Total
IPT group No (%) Non-IPT group No (%)
Past opportunistic infection(n = 587) Yes 145 (49.49%) 126 (42.86%) 271 (46.17%)
No 148 (50.51%) 168 (57.14%) 316 (53.83%)
WHO clinical stage Stage I/ II 256 (87.07%) 227 (77.21%) 483 (82.14%)
Stage III/ IV 38 (12.93%) 67 (22.79%) 105 (17.86%)
Functional status Working1 270 (91.84%) 250 (85.03%) 520 (88.44%)
Ambulatory2 22 (7.48%) 43 (14.63%) 65 (11.05%)
Bedridden3 2 (0.68%) 1 (0.34%) 3 (0.51%)
OI treatment other than INH (n = 584) Given4 143 (49.14%) 124 (42.32%) 267 (45.72%)
Not given 148 (50.86%) 169 (57.68%) 317 (54.28%)
Hemoglobin level (n = 532) <=10 mg/dl 16 (5.90%) 19 (7.28%) 35 (6.58%)
>10 mg/dl 255 (94.10%) 242 (92.72%) 497 (93.42%)
CD4 cells count (cells/μl) (n = 585) <350 84 (28.77%) 69 (23.55%) 153 (26.15%)
350 – 499 121 (41.44%) 116 (39.59%) 237 (40.51%)
> = 500 87 (29.79%) 108 (36.86%) 195 (33.33%)
Weight (kg) <40 3 (1.02%) 13 (4.42%) 16 (2.72%)
40-49 81 (27.55%) 87 (29.59%) 168 (28.57%)
50-60 117 (39.63%) 129 (43.88%) 246 (41.84%)
>60 93 (31.63%) 65 (22.11%) 158 (26.87%)
Follow-up outcome Alive 181 (61.56%) 105 (35.71%) 286 (48.64%)
Lost to follow up 66 (22.45%) 109 (37.07%) 175 (29.76%)
Entry to ART 20 (6.8%) 19 (6.46%) 39 (6.63%)
TB 13 (4.42%) 36 (12.24%) 49 (8.83%)
Other5 14 (4.76%) 25 (8.50%) 39 (6.63%)
Median CD4 cells count (cells/μl) 415 (IQR 328–786) 444 (IQR 357–613) 422 (IQR 344–589)
1Working: able to perform usual work in and out of the house.
2Ambulatory: able to perform activities for daily living.
3Bedridden: unable to perform activities for daily living.
4Cotrimoxazole, Fluconazole.
5Transferred out and dead.
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uals with relatively advanced immune-suppression and
non-adherence to therapy [24]. Our results suggest that
the difference in incidence of tuberculosis might be at-
tributed to the use of IPT that prevents progression of
latent infection to active disease.
This study showed that IPT offers a long term benefit
in HIV-infected individuals against tuberculosis with a
higher TB free survival particularly during the first threeTable 3 Incidence of tuberculosis per 100 person-year accord
on pre-ART follow up in, JUSH, 2013, N = 588
Group No. of cases of tuberculosis No.
IPT 13 586
non-IPT 36 711
Overall TB incidence 49 129years of follow up among IPT users. Therefore the use
of IPT during pre-ART care shows higher decrease in
cumulative risk of TB disease in HIV-infected patients.
This finding agrees with observational study conducted
in Spain [31].
Similarly, TB-free survival time was higher in IPT group
than non-IPT group. This finding was supported by stud-
ies done in South Africa and Namibia that showed higher
TB-free survival probability among IPT-group [15,21]. Ining to exposure category among HIV infected individuals
of PY Incidence rate of TB per 100 PY (95% CI per 100 PY)
.16 2.22 (1.29- 3.82)
.41 5.06 (3.65 - 7.02)
7.50 3.8 (2.85 - 4.99)
Table 4 Bivariate and multivariate cox proportional hazards model of incident TB among HIV infected individuals on
pre-ART follow-up in, JUSH, 2013, N = 584
Variables Category Crude hazard ratio (95% CI) ¥Adjusted hazard ratio (95% CI)
Age group (years) 15-29 1.00
30-39 0.88 (0.48 1.62)
39+ 0.38 (0.15 0.98)*
Sex (N = 587) Female 1.00
Male 0.61 (0.35 1.06)
Marital status Never married 1.00
Married 0.56 (0.28 1.12)
Separated 0.83 (0.29 2.35)
Divorced 0.72 (0.27 1.91)
Widowed 0.23 (0.05 1.02)
Level of education (N = 585) Primary 1.00
No education 1.85 (0.95 3.63)
Secondary 1.38 (0.67 2.85)
Tertiary 0.63 (0.15 2.74)
People per household (N = 583) <=2 1.00
>2 1.54 (0.76 3.09)
Tobacco use Yes 1.00
No 0.66 (0.35 1.25)
Alcohol use Yes 1.00
No 0.68 (0.37 1.23)
Past opportunistic infection (N = 587) No 1.00 1.00
Yes 2.57 (1.43 4.61)** 2.41 (1.33 4.34)
WHO clinical stage Stage I/ II 1.00 1.00
Stage III/ IV 3.39 (1.90 6.02)** 3.05 (1.61 5.81)**
Functional status Working 1.00
Ambulatory 1.29 (0.58 2.88)
Bedridden 5.65 (0.77 41.32)
IPT prophylaxis® Yes 1.00 1.00
No 1.95 (1.02 3.74) 2.02 (1.04 3.92)*
CD4
+cells count (cells/μl) (N = 585) > = 500 1.00 1.00
350 – 499 3.06 (1.47 6.37)** 2.87 (1.37 6.03)**
<350 2.34 (1.02 5.39)* 3.16 (1.04 3.92)**
*Statistically significant at p ≤ 0.05 **statistically significant at p ≤ 0.01.
®Exchanging the reference at adjusted level of analysis results in (aHR = 0.5).
¥Global test of proportional-hazards assumption for predictors fitted to Cox proportional hazard model was not significant (df = 5, ch2 = 7.04, p = 0.218).
Assebe et al. BMC Public Health  (2015) 15:346 Page 7 of 9contrary, recent trial study conducted in Botswana shows
that shorter median time to develop TB among individ-
uals who took IPT for 6 month [32]. This variation might
be due to higher risk of re-infection to tuberculosis and
inadequate power in latter study.
Our study revealed IPT use has contributed to a higher
reduction in hazard of acquiring tuberculosis than non-
IPT use. This finding was consistent with pooled estimate
of four trials carried out in Uganda, Haiti, USA and Kenya
that showed approximately the same level of reduction ofTB in adults infected with HIV [19]. It was also in agree-
ment with other studies conducted in Namibia, Brazil and
Ethiopia [16,17,21]. But a recent meta-analysis of ten trails
revealed that IPT use was associated with a smaller reduc-
tion of TB among HIV infected individuals [33]. In con-
trary, other studies conducted in Brazil, Tanzania and
Kenya showed that insignificant effect of IPT on the re-
duction of TB [22-24]. The smaller reduction of TB in
the meta-analysis might be due to inclusion of studies
from resource rich countries with low TB prevalence
Figure 1 Kaplan-Meier estimate of tuberculosis-free survival probability in IPT and non-IPT group, JUSH, 2013.
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Brazil, Tanzania and Kenya may be due to difference in
number of individuals taking IPT; high rate of transmis-
sion of new infection and insufficient duration of the
prophylaxis in subjects with relatively advanced immune-
suppression were among the possible reason for absence
of the IPT benefit in these studies [22-24].
This study showed that patients presenting with clin-
ical WHO stages III and IV is associated with higher
hazard of developing tuberculosis as compared to pa-
tients in clinical WHO stage I and II. The result was in
agreement with study conducted in South Africa and
Ethiopia [14,17,20]. This may be due to the fact that
HIV weakens the immune system and lead, more oppor-
tunistic infections are likely to occur.
Our study also revealed that patients who suffered
from opportunistic infection had higher hazard of devel-
oping TB as compared to those free of the infections in
the past. Finding from a clinical trial in Uganda and case
control study in Ethiopia agreed with our finding
[11,34]. In this study, among the determinant factors,
having lower CD4
+ count were associated with increased
relative hazard for developing TB. The risk of TB shows
a higher increase when CD4
+ cell counts fall below 350
cells/μl. This result is consistent with cohort studies that
show gradual increase of the risk of TB when CD4
+ cell
count falls down [15,17,31].
Strength and limitation of the study
This is one of the few studies in Ethiopia that explored
association of IPT provision with the development of TB
in individuals under pre-ART care. This study did have
some limitations that are shared with most studies. The
retrospective nature of the study design limited to in-
clude other factors that may influence the risk of TB
(house-hold income, housing condition).Conclusion and recommendation
Provision of TB preventive therapy to all eligible HIV-
infected individuals in high TB prevalence before they
reach to severe form of HIV disease is an important ap-
proach to prevent and control tuberculosis. This study
indicates that isoniazid preventive therapy confers a sig-
nificant reduction in TB incidence among HIV infected
individuals and adjustment for potential confounder
didn’t alter the estimate of its effectiveness.
Efforts should be strengthened in implementing the
widespread use of IPT among adult HIV-infected patients
through integration with intensified case finding and de-
velopment of operational guidelines for the implementa-
tion of IPT in HIV care and treatment settings.
HIV infected individuals with advanced immunosup-
pression and past episode of opportunistic infection were
at higher risk of developing tuberculosis, which implies
undertaking in depth TB screening and frequent follow up
among these patient is critical in order to prevent and
control tuberculosis. Further prospective studies might be
needed to establish the optimal duration of its protective
effect and the added benefit of isoniazid preventive ther-
apy (IPT) among people receiving antiretroviral therapy
should be established in the country.
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